Table 8.
Univariate and Multivariate Variables Associated with Pazopanib-Related Non-Hypertension Cardiovascular Toxicity
| Unadjusted (univariate analysis) | Adjusted (multivariate analysis)a | |||
|---|---|---|---|---|
|
| ||||
| OR | P-value | OR | P-value | |
| Age ≥ 60 years | 15.79 | 0.006 | 8.72 | 0.105 |
| Male (vs. female) | 0.39 | 0.329 | ||
| Hypertension | 0.90 | 1 | ||
| Diabetes | 0.93 | 1 | ||
| Dyslipidemia | 3.01 | 0.233 | ||
| CVA/TIAb | 8.61 | 0.067 | 2.77 | 0.430 |
| CAD/PAD | 3.36 | 0.418 | ||
| GFR < 60 ml/min/1.73m2 | 3.16 | 0.236 | ||
| LV Dysfunction | 3.21 | 0.327 | ||
| Dysrhythmia | 1.56 | 0.906 | ||
| BMI > 30 kg/m2 | 0.93 | 1 | ||
| Smoker | 1.07 | 1 | ||
| ACEi/ARB use | 1.84 | 0.608 | ||
| Beta Blocker use | 1.14 | 1 | ||
| Statin use | 2.23 | 0.441 | ||
OR odds ratio, CI confidence interval, CVA/TIA cerebrovascular accident/transient ischemic attack, CAD/PAD coronary artery/peripheral artery disease, GFR glomerular filtration rate, LV left ventricular, BMI body mass index, ACEI angiotensin converting enzyme, ARB angiotensin receptor blocker
a
Model includes gender, preexisting CVA/TIA, dyslipidemia, and GFR < 60 ml/min/1.73m2
b
CVA/TIA was a perfect predictor for a non-hypertension cardiovascular event. P values based on exact logistic regression